Autologous KRAS-targeted T-cell therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Autologous KRAS-targeted T-cell therapy, covering 2026-04-06 to 2026-04-06. Get the full timeline:
Most recent: Clinical Trial Update: Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer [Phase 1]